Carvana Co vs Johnson & Johnson — how do they compare? Carvana Co trades at $70.65 (market cap $50.41B), while Johnson & Johnson trades at $254.13 (market cap $611.07B). The key difference: Johnson & Johnson is far larger — about 12.1× Carvana Co's market cap, and Johnson & Johnson pays a 2.11% dividend while Carvana Co pays none. Which is the better fit depends on your goals.
| CVNA | JNJ | |
|---|---|---|
Market Cap | $50.41B | $611.07B |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $267.24 |
52-Week Low | $56.27 | $155.17 |
Enterprise Value | $53.06B | $644.01B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.11% |
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $65.02, down 1.23% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $20.32 billion in 2025 and a net income of $1.41 billion, though it missed Q3 2025 EPS estimates. Recent corporate actions include stock splits, and cash flow from operations remains positive at $1.04 billion in 2025. Analyst consensus is a Buy with a $93.62 price target, indicating significant upside potential from current levels.
The outlook for CVNA is mixed; robust revenue growth and improving profitability support bullish sentiment, but high valuation ratios (P/E of 37.65) and technical bearishness pose risks. Investors should weigh the company's scaling efficiency and market share gains against debt levels and competitive pressures in the e-commerce auto sector. The stock's proximity to support at $64 suggests near-term volatility, but analyst targets imply confidence in long-term value.
Johnson & Johnson (JNJ) trades at $257.77, up 0.31% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $94.19B, net income margin of 21.83%, and consistent earnings beats. Recent dividend declaration of $1.34 and positive analyst coverage with 52.5% buy ratings reinforce confidence. The current price sits near pivot point resistance at $258, with technical indicators showing bullish momentum from moving averages.
JNJ presents a compelling long-term investment with stable cash flows, strong profitability metrics, and defensive healthcare positioning. Upside potential exists toward the $281 consensus price target, though risks include rising debt-to-asset ratio (24.06% in 2025) and patent expiration headwinds. The stock's 60+ year dividend growth history provides income stability amid market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →